-
C153470-250mgCreatinol Phosphate.
-
C153470-25gCreatinol Phosphate.
-
C153470-5gCreatinol Phosphate.
-
C647301-10mgCrolibulin (EPC2407) is a tubulin polymerization inhibitor, with potent apoptosis induction and cell growth inhibition. Crolibulin has anti-tumor activity. Crolibulin also has cardiovascular toxicity and neurotoxicityIn VitroCrolibulin shows
-
C647301-25mgCrolibulin (EPC2407) is a tubulin polymerization inhibitor, with potent apoptosis induction and cell growth inhibition. Crolibulin has anti-tumor activity. Crolibulin also has cardiovascular toxicity and neurotoxicityIn VitroCrolibulin shows
-
C647301-50mgCrolibulin (EPC2407) is a tubulin polymerization inhibitor, with potent apoptosis induction and cell growth inhibition. Crolibulin has anti-tumor activity. Crolibulin also has cardiovascular toxicity and neurotoxicityIn VitroCrolibulin shows
-
C647301-5mgCrolibulin (EPC2407) is a tubulin polymerization inhibitor, with potent apoptosis induction and cell growth inhibition. Crolibulin has anti-tumor activity. Crolibulin also has cardiovascular toxicity and neurotoxicityIn VitroCrolibulin shows
-
C654971-1mlCrolibulin (EPC2407) is a tubulin polymerization inhibitor, with potent apoptosis induction and cell growth inhibition. Crolibulin has anti-tumor activity. Crolibulin also has cardiovascular toxicity and neurotoxicityIn VitroCrolibulin shows
-
C647993-100mgCRT0273750 is an autotaxin (ATX) inhibitor and modulates LPA levels in plasm (IC 50 = 0.014 μM). CRT0273750 can be used in ATX/LPA-dependent models of cancerIn VitroCRT0273750 shows high potency in both the biochemical (IC 50 = 0.01 μM) and plasma
-
C647993-10mgCRT0273750 is an autotaxin (ATX) inhibitor and modulates LPA levels in plasm (IC 50 = 0.014 μM). CRT0273750 can be used in ATX/LPA-dependent models of cancerIn VitroCRT0273750 shows high potency in both the biochemical (IC 50 = 0.01 μM) and plasma
-
C647993-1mgCRT0273750 is an autotaxin (ATX) inhibitor and modulates LPA levels in plasm (IC 50 = 0.014 μM). CRT0273750 can be used in ATX/LPA-dependent models of cancerIn VitroCRT0273750 shows high potency in both the biochemical (IC 50 = 0.01 μM) and plasma
-
C647993-25mgCRT0273750 is an autotaxin (ATX) inhibitor and modulates LPA levels in plasm (IC 50 = 0.014 μM). CRT0273750 can be used in ATX/LPA-dependent models of cancerIn VitroCRT0273750 shows high potency in both the biochemical (IC 50 = 0.01 μM) and plasma